- Home
- LQDA vs BSM Comparison
LQDA vs BSM Comparison
Compare LQDA & BSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- BSM
- Stock Information
- Founded
- LQDA 2004
- BSM 1876
- Country
- LQDA United States
- BSM United States
- Employees
- LQDA N/A
- BSM N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- BSM Oil & Gas Production
- Sector
- LQDA Health Care
- BSM Energy
- Exchange
- LQDA Nasdaq
- BSM Nasdaq
- Market Cap
- LQDA 2.5B
- BSM 2.5B
- IPO Year
- LQDA 2018
- BSM 2015
- Fundamental
- Price
- LQDA $25.00
- BSM $12.96
- Analyst Decision
- LQDA Strong Buy
- BSM Hold
- Analyst Count
- LQDA 9
- BSM 1
- Target Price
- LQDA $32.11
- BSM $13.00
- AVG Volume (30 Days)
- LQDA 2.2M
- BSM 528.7K
- Earning Date
- LQDA 11-12-2025
- BSM 11-03-2025
- Dividend Yield
- LQDA N/A
- BSM 9.26%
- EPS Growth
- LQDA N/A
- BSM N/A
- EPS
- LQDA N/A
- BSM 1.16
- Revenue
- LQDA $19,322,000.00
- BSM $413,675,000.00
- Revenue This Year
- LQDA $405.58
- BSM $10.58
- Revenue Next Year
- LQDA $373.93
- BSM $14.68
- P/E Ratio
- LQDA N/A
- BSM $11.14
- Revenue Growth
- LQDA 30.20
- BSM N/A
- 52 Week Low
- LQDA $9.68
- BSM $11.78
- 52 Week High
- LQDA $29.94
- BSM $15.66
- Technical
- Relative Strength Index (RSI)
- LQDA 45.82
- BSM 66.26
- Support Level
- LQDA $25.34
- BSM $12.48
- Resistance Level
- LQDA $28.00
- BSM $12.24
- Average True Range (ATR)
- LQDA 1.32
- BSM 0.21
- MACD
- LQDA -0.70
- BSM 0.11
- Stochastic Oscillator
- LQDA 0.50
- BSM 97.52
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.